Trials / Completed
CompletedNCT05477186
Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
A Phase 1, Open-label, Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 185 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Prevention of COVID-19 caused by SARS-CoV-2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CV0501 (3 μg) | Study vaccine was administered as a single intramuscular injection. |
| BIOLOGICAL | CV0501 (6 μg) | Study vaccine was administered as a single intramuscular injection. |
| BIOLOGICAL | CV0501 (12 μg) | Study vaccine was administered as a single intramuscular injection. |
| BIOLOGICAL | CV0501 (25 μg) | Study vaccine was administered as a single intramuscular injection. |
| BIOLOGICAL | CV0501 (50 μg) | Study vaccine was administered as a single intramuscular injection. |
| BIOLOGICAL | CV0501 (100 μg) | Study vaccine was administered as a single intramuscular injection. |
| BIOLOGICAL | CV0501 (200 μg) | Study vaccine was administered as a single intramuscular injection. |
Timeline
- Start date
- 2022-08-12
- Primary completion
- 2023-08-18
- Completion
- 2023-08-18
- First posted
- 2022-07-28
- Last updated
- 2025-02-21
- Results posted
- 2025-02-21
Locations
17 sites across 3 countries: United States, Australia, Philippines
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05477186. Inclusion in this directory is not an endorsement.